February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...

Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a ...

Number 4: Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its ...

In this article, we explore how aging impacts the musculoskeletal system and share expert-backed prevention tips to help you ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

Osteoporosis, often called a silent disease, weakens bones and increases the risk of fractures, making it a leading cause of ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.